CurrentmhnPolicy CP.PHAR.711

Clinical Policy: Cosibelimab-ipdl (Unloxcyt)

Defines medical necessity criteria, dosing limits, approval durations, and prior authorization documentation requirements for Unloxcyt (cosibelimab-ipdl) for commercially insured, HIM, and Medicaid members. Also references off-label/other-use referral policies and coding implications.

Policy Summary

Payermhn

PolicyClinical Policy: Cosibelimab-ipdl (Unloxcyt)

Policy CodePolicy CP.PHAR.711

Change TypeHCPCS coding update & policy creation

Effective Date03.01.25

Next Review Date

Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) demonstrating that the member meets all approval criteria.

SourceLink

POLICY UPDATE CHANGES

HCPCS code J9275 was added to the policy coding.

Policy created and P&T approval recorded.

1Covered Indication (FDA-approved)

1200 mg q3wMaximum Dose

300 mgVial Size

6 monthsTypical Initial Approval Duration

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Background: Cosibelimab-ipdl (Unloxcyt) is a PD-L1 blocking monoclonal antibody indicated for adults with locally advanced (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) who are not candidates for curative surgery or curative radiation. Scope: This policy defines medical necessity criteria, dosing limits (maximum 1,200 mg every 3 weeks / 4 vials), approval durations, and prior authorization documentation requirements for commercially insured, HIM, and Medicaid members and aligns coverage to the FDA indication and NCCN recommendations. Coverage stance: covered_with_criteria — therapy is covered when the policy's initial or continuation criteria are met. Off-label uses are not automatically covered and require guideline or peer-reviewed literature support and referral to the listed off-label policies when applicable.

Quick Policy Facts

Maximum dose per administration1,200 mg every 3 weeks (4 vials)

Vial size300 mg per single‑dose vial

Typical initial approval duration6 months (Medicaid/HIM and Commercial)

Covered Indication count1 FDA‑approved indication (locally advanced or metastatic cutaneous squamous cell carcinoma)

Initial Therapy Criteria — Cutaneous Squamous Cell Carcinoma

Initial Approval Criteria - Cutaneous Squamous Cell Carcinoma

Covered when ALL of the following are met:

ref

title

ref_format_error

Prior Authorization

Prior authorization required (J9275)

Prior authorization is required for cosibelimab‑ipdl billed under HCPCS code J9275. Requests must meet the policy's initial or continuation criteria as specified in the clinical policy; when dosing exceeds the standard limit for an indication, submit supporting evidence (guidelines or peer‑reviewed literature) to justify off‑label dosing.

Billing Rule

Dosing and billing alignment

Dose billed should not exceed 1,200 mg every 3 weeks (equivalent to 4 vials of 300 mg) unless a higher dose is supported by practice guidelines or peer‑reviewed literature and documented by the prescriber.

Initial Therapy Criteria — Other Diagnoses / Pathways

Initial Approval Criteria - Other diagnoses/indications

If not covered above, follow one of the pathways:

ANY of the following

If drug underwent a recent label change (within last 6 months): Refer to no coverage criteria policy for drugs on formulary/PDL for relevant line of business: CP.CPA.190 (commercial), HIM.PA.33 (marketplace), CP.PMN.255 (Medicaid)
If drug is NOT on formulary/PDL after recent label change: Refer to non-formulary policy for relevant line of business: CP.CPA.190 (commercial), HIM.PA.103 (marketplace), CP.PMN.16 (Medicaid)
For other off-label uses not listed in section III: Refer to off-label use policy for relevant line of business: CP.CPA.09 (commercial), HIM.PA.154 (marketplace), CP.PMN.53 (Medicaid)

Off-label use requirements: Requests for Unloxcyt for indications, ages, or dosing regimens outside the FDA-approved CSCC indication must be supported by submission of practice guidelines or peer‑reviewed literature; the prescriber must submit supporting evidence. When the request does not meet the policy’s listed criteria, the request should be referred to the applicable off-label use policy for the member’s line of business: CP.CPA.09 (commercial), HIM.PA.154 (marketplace), or CP.PMN.53 (Medicaid). Provider documentation (e.g., office notes, labs) demonstrating that the member meets approval criteria must be submitted.

Continuation Therapy Criteria — Cutaneous Squamous Cell Carcinoma

Continuation (Renewal) Criteria - Cutaneous Squamous Cell Carcinoma

Covered when ALL of the following are met:

ALL of the following

Prior receipt: Currently receiving medication via Centene benefit, or documentation supports that member has received Unloxcyt for a covered indication for at least 30 days
Response: Member is responding positively to therapy
Dose increase requirement (one of)
- New dose limit: New dose does not exceed 1,200 mg (4 vials) every 3 weeks
- New dose guideline support: New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence)
Regimen requirement: Prescribed regimen must be FDA-approved or recommended by NCCN

Documentation Required

Continuation documentation required

For continuation (renewal) requests, include documentation that the member has received Unloxcyt via the Centene benefit for at least 30 days and that the member is responding positively to therapy (e.g., office notes, treatment records).

Not Authorized Indications

Coverage not authorized for:

ALL of the following

Not authorized indications: Non-FDA approved indications which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policies CP.CPA.09 (commercial), HIM.PA.154 (marketplace), and CP.PMN.53 (Medicaid) or evidence of coverage documents

Denial Risk

Denial risk for unsupported off‑label uses

Requests for non‑FDA‑approved (off‑label) indications that lack sufficient supporting evidence will not be authorized. Refer such requests to the off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (marketplace), and CP.PMN.53 (Medicaid).

Applicable Codes

HCPCS - drug billing codeHCPCSCovered

J9275

Injection, cosibelimab-ipdl, 2 mg

Removed HCPCS / miscellaneous codes (historical)mixed

J3590	Unclassified biologics (removed)
C9399	Unclassified drugs or biologicals (removed)

Policy coding change: HCPCS code J9275 (Injection, cosibelimab-ipdl, 2 mg) was added to the policy; previously referenced miscellaneous/unclassified codes J3590 and C9399 were removed.

Provider Actions

Prior Authorization

Prior authorization requirements (J9275)

Prior authorization is required for J9275. Requests must meet the policy's initial or continuation criteria and, when requesting off‑label or higher-than‑standard doses, submit supporting evidence (practice guidelines or peer‑reviewed literature) to justify dosing.

Documentation Required

Acceptable supporting documentation

Submit supporting clinical documentation to demonstrate criteria are met. Acceptable documentation includes office chart notes, lab results, treatment records, and other clinical information showing diagnosis, oncologist involvement, duration of therapy, and response to treatment.

Office chart notes
Laboratory results
Treatment/infusion records
Other clinical information demonstrating response and duration

Billing Rule

Billing rule — maximum billed dose

Dose billed should not exceed 1,200 mg every 3 weeks (4 vials of 300 mg). Higher doses may be considered only if supported by practice guidelines or peer‑reviewed literature and documented by the prescriber.

Documentation Required

Renewal documentation and dose‑change requirements

For renewal requests document that the member has received Unloxcyt via the Centene benefit for at least 30 days and is responding positively to therapy. If requesting a dose increase at renewal, either the new dose must not exceed 1,200 mg q3w or be supported by guidelines/literature with prescriber documentation.

Clinical Evidence and Guidelines

Evidence sources: FDA Prescribing Information — Unloxcyt Prescribing Information, Checkpoint Therapeutics, Inc.; December 2024 and guideline referenced — NCCN Squamous Cell Skin Cancer, Version 1.2024. This policy aligns coverage to the FDA-approved indication for laCSCC and mCSCC and to NCCN recommendations referenced in the policy.

Definitions & Background

Definitions: CSCC (cutaneous squamous cell carcinoma): malignant tumor of the skin arising from squamous cells. laCSCC (locally advanced cutaneous squamous cell carcinoma): locally advanced disease not amenable to curative surgery or radiation. mCSCC (metastatic cutaneous squamous cell carcinoma): disease with distant spread. PD-L1 (programmed death ligand-1): the ligand targeted by cosibelimab-ipdl. Cosibelimab-ipdl (Unloxcyt) is a PD-L1 blocking monoclonal antibody indicated for adults with laCSCC or mCSCC who are not candidates for curative surgery or radiation.

Revision History

2024-12-26created

Policy created (Policy created date 12.26.24)

2025-02-25approval

P&T approval recorded (P&T approval date 02.25)

2025-03-01material_changeLatest

HCPCS code J9275 (Injection, cosibelimab‑ipdl, 2 mg) was added and codes J3590 and C9399 were removed

Policy Summary

Payermhn

PolicyClinical Policy: Cosibelimab-ipdl (Unloxcyt)

Policy CodePolicy CP.PHAR.711

Change TypeHCPCS coding update & policy creation

Effective Date03.01.25

Next Review Date

Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) demonstrating that the member meets all approval criteria.

SourceLink

On This Page